A New Alternative To Warfarin As A Blood Thinner.
A novel blood thinner might be a reasonable alternative to warfarin (Coumadin), the standard for decades to expound patients with the dangerous heart rhythm disorder known as atrial fibrillation. In digging presented Monday at the American Heart Association's annual meeting in Chicago, researchers reported that rivaroxaban (Xarelto) proved to be just as excellent as warfarin, and possibly superior. Rivaroxaban also reduced the imperil of serious bleeding events, which is the most troubling side effect of warfarin.
Dabigatran (Pradaxa), another newer-generation blood thinner, was approved by the US Food and Drug Administration to treat atrial fibrillation up to date month. This latest study was sponsored by Johnson & Johnson Pharmaceutical Research & Development and Bayer Healthcare, the makers of rivaroxaban.
Warfarin is the sheet anchor for the treatment of patients with atrial fibrillation, which affects some 2,2 million Americans. During atrial fibrillation, the heart's two stingy uppermost chambers - called the atria - quiver rather than forge methodically, raising the risk of blood clots and eventually a stroke. The drug is impressive in reducing the risk of stroke, but it has significant drawbacks, including the bleeding risk and difficulties with dosing and monitoring.
And "In October of 2006, the FDA US Food and Drug Administration issued a black-box augury for warfarin due to a growing awareness of its hazards in routine clinical practice," said Dr Elaine Hylek, who spoke at a Monday front-page news conference on the findings, although she was not involved with the mammoth study. "The prerequisite for monitoring has relegated millions of people to no therapy or ineffective therapy because of deficiency of access to monitoring and an intense search for an alternative with more predictable dose responses".
Hylek is an associate professor of prescription at Boston University School of Medicine and reported ties with several pharmaceutical companies. The modern development trial, which scientists said was the largest of its kind, involved an international collaboration of researchers in 45 countries, 1215 medical centers and 14269 patients with atrial fibrillation who had already had a iota or who had endanger factors for a stroke.
Showing posts with label rivaroxaban. Show all posts
Showing posts with label rivaroxaban. Show all posts
Thursday 29 November 2018
Sunday 3 August 2014
New Blood Thinner Pill For Patients With Deep Vein Thrombosis
New Blood Thinner Pill For Patients With Deep Vein Thrombosis.
A experimental anti-clotting pill, rivaroxaban (Xarelto), may be an effective, within and safer healing for patients coping with deep-vein thrombosis (DVT), a pair of new studies indicate. According to the research, published online Dec 4, 2010 in the New England Journal of Medicine, the deaden could sell a new option for these potentially life-threatening clots, which most typically mode in the lower leg or thigh. The findings are also slated for presentation Saturday at the annual joining of the American Society of Hematology (ASH), in Orlando, Fla.
And "These study outcomes may maybe change the way that patients with DVT are treated," study author Dr Harry R Buller, a professor of prescription at the Academic Medical Center at the University of Amsterdam, said in an ASH announcement release. "This new treatment regimen of oral rivaroxaban can potentially come to blood clot therapy easier than the current standard treatment for both the patient and the physician, with a single-drug and honest fixed-dose approach".
Another heart expert agreed. "Rivaroxiban is at least as effective as the older treat warfarin and seems safer. It is also far easier to use since it does not require blood testing to mediate the dose," said cardiologist Dr Alan Kadish, currently president of Touro College in New York City.
The about was funded in part by Bayer Schering Pharma, which markets rivaroxaban maximum the United States. Funding also came from Ortho-McNeil, which will market the drug in the United States should it pick up US Food and Drug Administration approval. In March 2009, an FDA admonitory panel recommended the drug be approved, but agency review is ongoing pending further study.
The authors note that upwards of 2 million Americans wisdom a DVT each year. These lap clots - sometimes called "economy flight syndrome" since they've been associated with the immobilization of large flights - can migrate to the lungs to form potentially deadly pulmonary embolisms. The in vogue standard of care typically involves treatment with relatively well-known anti-coagulant medications, such as the viva voce medication warfarin (Coumadin) and/or the injected medication heparin.
While effective, in some patients these drugs can stir unstable responses, as well as problematic interactions with other medications. For warfarin in particular, the possibility also exists for the development of severe and life-threatening bleeding. Use of these drugs, therefore, requires consuming and continuous monitoring. The search for a safer and easier to administer curing option led Buller's team to analyze two sets of data: One that corroded rivaroxaban against the standard anti-clotting drug enoxaparin (a heparin-type medication), and the second which compared rivaroxaban with a placebo.
A experimental anti-clotting pill, rivaroxaban (Xarelto), may be an effective, within and safer healing for patients coping with deep-vein thrombosis (DVT), a pair of new studies indicate. According to the research, published online Dec 4, 2010 in the New England Journal of Medicine, the deaden could sell a new option for these potentially life-threatening clots, which most typically mode in the lower leg or thigh. The findings are also slated for presentation Saturday at the annual joining of the American Society of Hematology (ASH), in Orlando, Fla.
And "These study outcomes may maybe change the way that patients with DVT are treated," study author Dr Harry R Buller, a professor of prescription at the Academic Medical Center at the University of Amsterdam, said in an ASH announcement release. "This new treatment regimen of oral rivaroxaban can potentially come to blood clot therapy easier than the current standard treatment for both the patient and the physician, with a single-drug and honest fixed-dose approach".
Another heart expert agreed. "Rivaroxiban is at least as effective as the older treat warfarin and seems safer. It is also far easier to use since it does not require blood testing to mediate the dose," said cardiologist Dr Alan Kadish, currently president of Touro College in New York City.
The about was funded in part by Bayer Schering Pharma, which markets rivaroxaban maximum the United States. Funding also came from Ortho-McNeil, which will market the drug in the United States should it pick up US Food and Drug Administration approval. In March 2009, an FDA admonitory panel recommended the drug be approved, but agency review is ongoing pending further study.
The authors note that upwards of 2 million Americans wisdom a DVT each year. These lap clots - sometimes called "economy flight syndrome" since they've been associated with the immobilization of large flights - can migrate to the lungs to form potentially deadly pulmonary embolisms. The in vogue standard of care typically involves treatment with relatively well-known anti-coagulant medications, such as the viva voce medication warfarin (Coumadin) and/or the injected medication heparin.
While effective, in some patients these drugs can stir unstable responses, as well as problematic interactions with other medications. For warfarin in particular, the possibility also exists for the development of severe and life-threatening bleeding. Use of these drugs, therefore, requires consuming and continuous monitoring. The search for a safer and easier to administer curing option led Buller's team to analyze two sets of data: One that corroded rivaroxaban against the standard anti-clotting drug enoxaparin (a heparin-type medication), and the second which compared rivaroxaban with a placebo.
Subscribe to:
Posts (Atom)